Suppr超能文献

6%羟乙基淀粉130/0.4与晶体溶液对冠状动脉搭桥术后肾脏结构损伤标志物的影响:一项前瞻性试验的事后亚组分析

Influence of 6% Hydroxyethyl Starch 130/0.4 Versus Crystalloid Solution on Structural Renal Damage Markers After Coronary Artery Bypass Grafting: A Post Hoc Subgroup Analysis of a Prospective Trial.

作者信息

Datzmann Thomas, Hoenicka Markus, Reinelt Helmut, Liebold Andreas, Gorki Hagen

机构信息

Department of Cardiac Anesthesiology, University Hospital Ulm, Ulm, Germany.

Department Cardiothoracic and Vascular Surgery, University Hospital Ulm, Ulm, Germany.

出版信息

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):205-211. doi: 10.1053/j.jvca.2017.05.041. Epub 2017 May 25.

Abstract

OBJECTIVE

The restriction of hydroxyethyl starch (HES) has mandated changes in volume management based on data of critically ill patients. Reliable data of structural renal damage after HES treatment in cardiac surgical patients are lacking. The influence of 6% HES 130/0.4 was investigated in this study.

DESIGN

An exploratory post hoc subgroup analysis of a prospective trial was performed.

SETTING

The study was carried out at a university hospital.

PARTICIPANTS

Forty-four low-risk cardiac surgical patients were examined.

INTERVENTIONS

Twenty-two patients received only crystalloid solutions, and 22 were treated with balanced 6% HES 130/0.4.

MEASUREMENTS AND MAIN RESULTS

Functional renal parameters and the structural biomarkers α-glutathione S-transferase, kidney injury molecule-1, liver fatty acid-binding protein, and neutrophil gelatinase-associated lipocalin were investigated. Volume balances, vasopressor dosages, blood losses, and coagulation parameters were compared. Most functional and structural renal parameters did not differ between the groups (serum creatinine p = 0.8380). Liver fatty acid-binding protein was transiently higher in the HES group only at 24 hours postoperatively (p = 0.0002). No differences in mortality, acute kidney injury, and need for renal replacement therapy were observed. Blood coagulation was significantly more compromised in the HES group at intensive care unit arrival (factor II, p = 0.0012; factor X, p = 0.0031; thrombocytes, p = 0.0010). Blood losses, and vasopressor dosages tended to be higher in HES-treated patients without significance.

CONCLUSION

Overall, the values and time courses of the biomarkers used did not indicate evidence of a mechanism for tubular injury caused by HES.

摘要

目的

羟乙基淀粉(HES)的使用限制促使基于重症患者数据对容量管理进行调整。目前缺乏心脏手术患者接受HES治疗后发生结构性肾损伤的可靠数据。本研究调查了6% HES 130/0.4的影响。

设计

对一项前瞻性试验进行探索性事后亚组分析。

地点

本研究在一家大学医院开展。

参与者

检查了44例低风险心脏手术患者。

干预措施

22例患者仅接受晶体溶液治疗,22例接受平衡型6% HES 130/0.4治疗。

测量指标及主要结果

研究了肾功能参数以及结构性生物标志物α-谷胱甘肽S-转移酶、肾损伤分子-1、肝脂肪酸结合蛋白和中性粒细胞明胶酶相关脂质运载蛋白。比较了容量平衡、血管升压药剂量、失血量和凝血参数。两组间大多数功能和结构性肾参数无差异(血清肌酐p = 0.8380)。仅在术后24小时,HES组的肝脂肪酸结合蛋白短暂升高(p = 0.0002)。未观察到死亡率、急性肾损伤和肾脏替代治疗需求方面的差异。在重症监护病房入院时,HES组的凝血功能明显更差(凝血因子II,p = 0.0012;凝血因子X,p = 0.0031;血小板,p = 0.0010)。HES治疗患者的失血量和血管升压药剂量往往更高,但无统计学意义。

结论

总体而言,所使用生物标志物的值和时间进程未显示出HES导致肾小管损伤的机制证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验